Efficacy of Anti-VEGF Treatments For Diabetic Retinopathy Explored

Share this content:
Researchers compared the efficacy of aflibercept, bevacizumab, and ranibizumab.
Researchers compared the efficacy of aflibercept, bevacizumab, and ranibizumab.

HealthDay News — Three anti-vascular endothelial growth factor (anti-VEGF) treatments are associated with low rates of diabetic retinopathy (DR) worsening, according to a study published online in JAMA Ophthalmology.

Susan B. Bressler, MD, from Johns Hopkins University, and colleagues conducted preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during 2 years of treatment with aflibercept (2 mg), bevacizumab (1.25 mg), or ranibizumab (0.3 mg).

The researchers found that at 1 year, among 423 nonproliferative DR (NPDR) eyes, 44 of 141 (31.2%) treated with aflibercept, 29 of 131 (22.1%) with bevacizumab, and 57of 151 (37.7%) with ranibizumab had improvement of DR severity (P =.004 for aflibercept vs bevacizumab, P =.01 for ranibizumab vs bevacizumab, and P =.51 for aflibercept vs ranibizumab). At 2 years, no treatment group differences were identified. Among the 93 eyes with proliferative DR (PDR) at baseline, 1-year improvement rates were 75.9% for aflibercept, 31.4% for bevacizumab, and 55.2% for ranibizumab (P <.001 for aflibercept vs bevacizumab, P =.09 for ranibizumab vs bevacizumab, and P =.02 for aflibercept vs ranibizumab). These rates and group differences were maintained at 2 years.

"All 3 anti-VEGF treatments were associated with low rates of DR worsening. These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME," conclude the authors.

Disclosures: Several authors report financial ties to the pharmaceutical industry.

Reference

Bressler SB, Liu D, Glassman AR, et al; for the Diabetic Retinoapthy Clinical Research Network. Change in diabetic retinopathy through 2 years. Secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab [published online April 27, 2017]. JAMA Ophthalmol. doi: 10.1001/jamaophthalmol.2017.0821

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus